CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc., a targeted therapy, immuno-oncology company focused on developing potential first-in-class oncology drugs (“MAIA”), announced today that it has appointed Joseph F. McGuire as Chief Financial Officer. MAIA has also provided a corporate update announcing the creation of a wholly-owned subsidiary in Australia to execute on its global development strategy.
“I am pleased to welcome Joe to our leadership team as Chief Financial Officer. His financial leadership, strong business acumen and significant company building expertise will add value to the company,” stated Vlad Vitoc, MD, MAIA’s Chairman and Chief Executive Officer. “We are also pleased to have established our Australian subsidiary, which is a critical component to executing on our global development strategy for THIO-101.”
Mr. McGuire brings over 30 years of experience to MAIA, having served as Chief Financial Officer for several privately held and publicly traded companies in the health care, financial services, investment, and manufacturing industries. In these roles, Mr. McGuire’s responsibilities included SEC financial reporting, investor relations, corporate governance, legal and audit liaison, and team-building. He began his career with Price Waterhouse, where he was a certified public accountant, and later held management positions with Dean Witter Reynolds and Paine Webber, Inc. Mr. McGuire received a Bachelor of Science in accounting from the University of Notre Dame. Mr. McGuire will serve on the executive management team and will lead the company’s finance functions.
"It is extremely exciting to join MAIA,” said Mr. McGuire. “The company’s strong leadership team, recognized partners, supportive investors, and commitment to transforming the cancer treatment paradigm make this a very compelling opportunity. I look forward to helping MAIA execute on our strategic plan as we advance our cancer pipeline to patients and deliver meaningful growth to our stockholders.”
In addition to the appointment of Mr. McGuire as Chief Financial Officer, MAIA also announced today that is has established a wholly owned subsidiary in Australia, MAIA Biotechnology Australia Pty Ltd. The company has created the subsidiary to conduct the pre-clinical and clinical research activities that will support the development of lead product candidates including the initiation of the THIO-101 Phase 2 study for patients with Non-Small Cell Lung Cancer.
About MAIA Biotechnology, Inc.
MAIA Biotechnology, Inc. is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Drug candidates include (i) THIO, a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of telomerase-positive cancer cells and (ii) two compound families in pre-clinical evaluation for the treatment of prostate cancer and breast cancer using a potentially novel mode of action targeting androgen receptor (AR) and direct FKBP52 co-chaperone inhibition. For more information, please visit www.maiabiotech.com.
Forward Looking Statements
MAIA cautions that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as “may,” “might,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. In this release, unless the context requires otherwise, “MAIA,” “Company,” “we,” “our,” and “us” refers to MAIA Biotechnology, Inc. and its subsidiaries.